IPD
Delivery · Highdata caveat$26M9mo
ImpediMed Limited
Medical Devices · Oncology
Medical device company commercialising the SOZO bioimpedance spectroscopy platform, FDA-cleared for lymphedema detection and heart failure fluid monitoring, with 90%+ reimbursement coverage across 27 US states.
Data HealthTrials1 of 1 active · stale enrollment
Cash data from Mar 2026 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$12.7M
Mar 2026 4C
Runway
9moCAUTION
Based on Mar 2026 4C
Market Cap
$26M
Burn Rate
$4.5M/qtr
Mar 2026 4C
Shares Outstanding
4.4B
Pipeline Assets
3
Latest Insightprice-sensitive announcements & broker notes
Price-sensitiveCapital Raise9 June 2026
Oversubscribed Share Purchase Plan Successfully Completed
$2.1MSpp·at$0.007·300.0M shares
3M Price
IPD.ASX$0.006-62.5% 3M
Low $0.006High $0.017
Pipeline Assets (3)
Capital Raises & Buybacks
12mo dilution 53.2%12mo $24M5 raises
Current shares outstanding: 4.4B
Placement
SPP
Other ticker dataInsider activity, holders, grants, publications
expand ›
Insider activity, holders, grants, publications
Director Transactions
5 transactionsLast 90dNet Buy
Buys5+5 vs prior
Sells0
Buy Value$17k
warning5 directors bought within 30 days (06-02 – 06-02) — $17k total
Catalysts (10)· 3 upcoming · 7 past
Profitability / cash flow breakeven milestone
UpcomingExpectedarrow_upwardHigh31 Dec 2026
US reimbursement expansion — ongoing
UpcomingConfirmedarrow_upwardHigh31 Dec 2026
AstraZeneca CKD/HF Phase IIb trial data
UpcomingSpeculativeremoveMed30 June 2027
expand_more7 past catalysts
Track RecordDelivery Consistency Index
expand ›
Delivery Consistency Index
Historical delivery and spending consistency. Data is limited for recently added companies.
Delivery Consistency Index
Delivery
High100/100
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
High92/100(limited data)
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Hit 7 of 7 guided dates· rolling 2yr· of 10 tracked
Filed 1 of 1 4Cs on time· statutory deadline· 1 filing without matched announcement
What drove these scores · rolling 2yr
arrow_drop_down
High admin overhead — Only 11% of opex directed to R&D
arrow_drop_up
Stable burn rate — 2% quarterly variation — consistent spend
·
ImpediMed announces a successful $15.2 million Capital Raise — Delivered on time
·
Proposed issue of securities - IPD — Delivered on time
·
Share Purchase Plan Opens — Delivered on time
·
Share Purchase Plan - Letters to Shareholders — Delivered on time
·
Share Purchase Plan Close Date — Delivered on time
·
CEO Business Update — Delivered on time
·
Oversubscribed Share Purchase Plan Successfully Completed — Delivered on time
·
Phase 3+ thresholds — Burn rate variability thresholds adjusted for late-stage development
Completed catalysts
✓ImpediMed announces a successful $15.2 million Capital Raise
On time
✓Proposed issue of securities - IPD
On time
✓Share Purchase Plan Opens
On time
✓Share Purchase Plan - Letters to Shareholders
On time
✓Share Purchase Plan Close Date
On time
✓CEO Business Update— ImpediMed announced organizational restructuring with two new leadership roles focused on driving SOZO device sales, utilization and retention. The company reported encouraging unit sales momentum, significant physician engagement from major conferences, and growing commercial traction in weight management and body composition segments, supported by recent capital raising.
On time
✓Oversubscribed Share Purchase Plan Successfully Completed
On time
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Clinical Trials(4)
1 activeClinicalTrials.gov ↗
NAActive Not RecruitingEnrollment stale · 2992d
20-30 mmHg compression sleeve and gauntletManual Lymphatic Drainage
Subclinical Lymphedema Treatment Study
Breast Cancer-related Subclinical Lymphedema
RandomizedOpen Label18 Years+
Primary endpoint L-dex scores
ENROL267
no manual snapshots — enter via record_enrollment.py
Announcements(20)
trending_up
Capital RaisePSauto_awesome
Oversubscribed Share Purchase Plan Successfully Completed9 June 2026
expand_more205KB
person
Insider Tradeauto_awesome
Change of Director's Interest Notice - Mr Erik Anderson3 June 2026
expand_more154KB
person
Insider Tradeauto_awesome
Change of Director's Interest Notice - Ms Fiona Bones3 June 2026
expand_more151KB
person
Insider Tradeauto_awesome
Change of Director's Interest Notice - Ms Janelle Delaney3 June 2026
expand_more173KB
person
Insider Tradeauto_awesome
Change of Director's Interest Notice - Ms Emmanuel-Donnelly3 June 2026
expand_more154KB